| __timestamp | HUTCHMED (China) Limited | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72049000 | 4050200000 |
| Thursday, January 1, 2015 | 110777000 | 5047100000 |
| Friday, January 1, 2016 | 156328000 | 6078400000 |
| Sunday, January 1, 2017 | 175820000 | 6931500000 |
| Monday, January 1, 2018 | 143944000 | 6861900000 |
| Tuesday, January 1, 2019 | 160152000 | 7056300000 |
| Wednesday, January 1, 2020 | 188519000 | 8149300000 |
| Friday, January 1, 2021 | 258234000 | 12310800000 |
| Saturday, January 1, 2022 | 311103000 | 9765700000 |
| Sunday, January 1, 2023 | 384447000 | 8988300000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Over the past decade, Viatris Inc. and HUTCHMED (China) Limited have showcased distinct trajectories in their cost of revenue. From 2014 to 2023, Viatris Inc. consistently reported higher costs, peaking in 2021 with a staggering 12.3 billion USD, reflecting its expansive operations. In contrast, HUTCHMED's costs, though significantly lower, have shown a remarkable growth of over 400% from 2014 to 2023, indicating its aggressive market expansion. Notably, 2021 marked a pivotal year for both companies, with Viatris reaching its zenith and HUTCHMED crossing the 250 million USD threshold. This data not only highlights the operational scale of these giants but also underscores the strategic shifts in the pharmaceutical industry, where cost management and growth are intricately linked.
Cost of Revenue: Key Insights for Johnson & Johnson and HUTCHMED (China) Limited
Cost of Revenue Trends: AstraZeneca PLC vs HUTCHMED (China) Limited
Cost Insights: Breaking Down Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited's Expenses
Cost Insights: Breaking Down Viatris Inc. and Walgreens Boots Alliance, Inc.'s Expenses
Analyzing Cost of Revenue: Viatris Inc. and Lantheus Holdings, Inc.
Cost Insights: Breaking Down Viatris Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Viatris Inc. vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down Viatris Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs HUTCHMED (China) Limited
Corcept Therapeutics Incorporated vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Perrigo Company plc and HUTCHMED (China) Limited
Cost of Revenue Comparison: HUTCHMED (China) Limited vs Xencor, Inc.